CEA, IRTSV, Biologie à Grande Echelle, F-38054 Grenoble, France.
Mol Cell Proteomics. 2012 Feb;11(2):M111.008235. doi: 10.1074/mcp.M111.008235. Epub 2011 Nov 11.
Development of new biomarkers needs to be significantly accelerated to improve diagnostic, prognostic, and toxicity monitoring as well as therapeutic follow-up. Biomarker evaluation is the main bottleneck in this development process. Selected Reaction Monitoring (SRM) combined with stable isotope dilution has emerged as a promising option to speed this step, particularly because of its multiplexing capacities. However, analytical variabilities because of upstream sample handling or incomplete trypsin digestion still need to be resolved. In 2007, we developed the PSAQ™ method (Protein Standard Absolute Quantification), which uses full-length isotope-labeled protein standards to quantify target proteins. In the present study we used clinically validated cardiovascular biomarkers (LDH-B, CKMB, myoglobin, and troponin I) to demonstrate that the combination of PSAQ and SRM (PSAQ-SRM) allows highly accurate biomarker quantification in serum samples. A multiplex PSAQ-SRM assay was used to quantify these biomarkers in clinical samples from myocardial infarction patients. Good correlation between PSAQ-SRM and ELISA assay results was found and demonstrated the consistency between these analytical approaches. Thus, PSAQ-SRM has the capacity to improve both accuracy and reproducibility in protein analysis. This will be a major contribution to efficient biomarker development strategies.
为了改善诊断、预后和毒性监测以及治疗随访,需要显著加快新生物标志物的开发。生物标志物评估是这一开发过程中的主要瓶颈。选择反应监测(SRM)与稳定同位素稀释相结合已成为加速这一步骤的一种很有前途的选择,尤其是因为其具有多重检测能力。然而,由于上游样本处理或不完全胰蛋白酶消化,仍然存在分析变异性问题需要解决。2007 年,我们开发了 PSAQ™方法(蛋白质标准绝对定量),该方法使用全长同位素标记蛋白标准来定量目标蛋白。在本研究中,我们使用经过临床验证的心血管生物标志物(LDH-B、CKMB、肌红蛋白和肌钙蛋白 I)来证明 PSAQ 和 SRM 的结合(PSAQ-SRM)可以在血清样本中实现高度准确的生物标志物定量。我们使用多重 PSAQ-SRM 测定法来定量分析心肌梗死患者的临床样本中的这些生物标志物。我们发现 PSAQ-SRM 与 ELISA 检测结果之间具有良好的相关性,并证明了这些分析方法之间的一致性。因此,PSAQ-SRM 有能力提高蛋白质分析的准确性和重现性。这将是对高效生物标志物开发策略的重大贡献。